Daniel M. Geynisman
Fox Chase Cancer Center(US)Temple University Health System(US)
Publications by Year
Research Areas
Bladder and Urothelial Cancer Treatments, Cancer Immunotherapy and Biomarkers, Urinary and Genital Oncology Studies, Renal cell carcinoma treatment, Multiple and Secondary Primary Cancers
Most-Cited Works
- → Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology(2019)443 cited
- → Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial(2021)399 cited
- → Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study(2019)173 cited
- → Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer(2023)162 cited
- → Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011(2015)158 cited
- → The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease(2015)146 cited
- → Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma(2022)135 cited
- → Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors(2017)133 cited
- → Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma(2024)132 cited
- → Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer(2020)130 cited